US 12,201,556 B2
Porous structures for extended release drug delivery devices
Randolph E. Campbell, South San Francisco, CA (US); Kevin W. Sacherman, South San Francisco, CA (US); Kathleen COgan Farinas, South San Francisco, CA (US); Signe Erickson, South San Francisco, CA (US); and Jeremy Boyette, South San Francisco, CA (US)
Assigned to ForSight Vision4, Inc., South San Francisco, CA (US)
Filed by ForSight Vision4, Inc., South San Francisco, CA (US)
Filed on Jul. 29, 2022, as Appl. No. 17/877,643.
Application 17/877,643 is a division of application No. 15/777,593, granted, now 11,432,959, previously published as PCT/US2016/062944, filed on Nov. 18, 2016.
Claims priority of provisional application 62/258,127, filed on Nov. 20, 2015.
Claims priority of provisional application 62/258,054, filed on Nov. 20, 2015.
Prior Publication US 2023/0072346 A1, Mar. 9, 2023
Int. Cl. A61F 9/00 (2006.01); A61M 5/142 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 9/0026 (2013.01); A61F 2250/0067 (2013.01); A61F 2250/0068 (2013.01); A61M 5/14276 (2013.01); A61M 2205/04 (2013.01); A61M 2205/125 (2013.01); A61M 2205/75 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A therapeutic device for extended release drug delivery, the device comprising:
a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir;
a porous structure coupled near the outlet of the reservoir, the porous structure formed of sintered material and configured to control a diffusion rate of the therapeutic agent through the outlet of the reservoir; and
a barrier layer coupled to the reservoir on or adjacent an inner-facing surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet,
wherein the barrier layer is configured to block passage of contaminants from entering the eye through the porous structure, or is configured to block passage of contaminants from entering the reservoir through the porous structure, or is configured to block passage contaminants from entering the eye and the reservoir through the porous structure,
and wherein the barrier layer mitigates a bolus release of the therapeutic agent through the porous structure upon an increase in pressure within the reservoir.